Monarin

Indonesia • Dexa Medica

Indication

Monarin is indicated in adults for the prophylaxis and chronic treatment of asthma, including the prevention of exercise-induced bronchoconstriction.

Composition

Montelukast 10 mg

Package

3 blisters of 10 tablets

Dosage Forms

Tablet

ATC Classification

R03D

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Caution
This item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.
Pregnancy
Caution
This item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.
Lactation
Caution
This item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Dosage

0 to 15 Years Old

Montelukast 10 mg tablets should not be prescribed.

15 Years Old and Above

Asthma:
Monarin should be taken once daily in the evening (one-10 mg tablet)

Exercise-Induced Bronchoconstriction (EIB):
For prevention of EIB, a single dose (one-10 mg tablet) of Monarin should be taken at least 2 hours before exercise.

An additional dose of Monarin should not be taken within 24 hours of a previous dose. Patients already taking Monarin daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Daily administration of Monarin for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

Administration

The therapeutic effect of montelukast on parameters of asthma control occurs within one day. Montelukast may be taken with or without food. Patients should be advised to continue taking montelukast even if their asthma is under control, as well as during periods of worsening asthma.

Patients with Renal Impairment

No dosage adjustment is necessary for patients with renal insufficiency.

Patients with Mild to Moderate Hepatic Impairment

No dosage adjustment is necessary for patients with mild to moderate hepatic impairment.